Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin


Anthrax is a serious infectious disease caused by bacteria known as Bacillus anthracis. Anthrax-contaminated spores can be found naturally in soil and they commonly affect domestic and wild animals around the world. Although rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products.

CDC researchers have developed a lateral flow immunoassay using monoclonal antibodies against Bacillus anthracis toxin and its components, lethal factor (LF) and protective antigen (PA). These antibodies have been screened and optimized into anti-LF and anti-PA pairs, which allows capture and detection of the anthrax antigens. These antibodies can be used in multiple combinations for rapid, simple, sensitive and specific assays for culture-free anthrax diagnosis. The lateral flow immunoassay can be used as a rapid point-of-care assay for detection of anthrax antigens like LF before onset of symptoms, which may allow prophylactic measures, early intervention and successful disease treatment. In addition to this, these antibodies can be used in enzyme linked immunoassays and hybrid real-time PCR immunodetection assays for anthrax diagnosis, as well as research.

Potential Commercial Applications: Competitive Advantages:
  • Lateral flow immunoassay for detection of anthrax antigens before symptom onset
  • Anthrax specific enzyme-linked immunoassay
  • Hybrid real-time PCR and immunodetection assay for anthrax diagnosis
  • Quality control for inactivated anthrax toxin preparations used in anthrax vaccine
  • Livestock screening
  • Diagnosis in the field to identify livestock/wildlife outbreaks earlier and potentially avoid spillover to human cases
  • Research tools
 
  • Antibodies targeting multiple sites in anthrax toxin increase the sensitivity of detection
  • Monoclonal antibodies allow better diagnostic specificity than polyclonal antibodies
  • Adaptable for high-throughput screening assays
  • Allows culture-free diagnosis that can help in early intervention and successful disease control
  • These monoclonal antibodies can be used to improve currently available anthrax diagnostics


Related Invention(s):
E-196-2013-0


Inventors:

Conrad Quinn (CDC)  ➽ more inventions...

Jason Goldstein (CDC)  ➽ more inventions...

Dennis Bagarozzi (CDC)  ➽ more inventions...

Panagiotis Maniatis (CDC)  ➽ more inventions...

Nazia Kamal (CDC)  ➽ more inventions...

Monica Epperson (CDC)  ➽ more inventions...


Intellectual Property:
Patent protection is not being pursued for this technology.

Collaboration Opportunity:

The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin. For collaboration opportunities, please contact CDC TTO at tto@cdc.govor 1-404-639-1330.


Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-071-2016-0
Updated: Jun 22, 2018